从资金流向上来看，当日医药商业板块主力资金净流出2.28亿元，游资资金净流出2472.38万元，散户资 金净流入2.52亿元。医药商业板块个股资金流向见下表： 证券之星消息，11月28日医药商业板块较上一交易日上涨0.29%，海王生物领涨。当日上证指数报收于 3888.6，上涨0.34%。深证成指报收于12984.08，上涨0.85%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000078 | 海壬生物 | 3.40 | 10.03% | 410.67万 | 13.33 Z | | 603122 | 合富中国 | 23.82 | 7.49% | 108.60万 | 24.53亿 | | 600538 | 国发股份 | 6.45 | 2.06% | 14.97万 | 9550.39万 | | 301126 | 达嘉维康 | 12.83 | 0.94% | 11.65万 | 1.50亿 | | 000411 | 英特集团 | 12.04 | 0.92% | 13. ...

Group 1 - The core point of the article is the resignation of Mr. Chen Changbing from the position of Deputy General Manager of China National Pharmaceutical Group Corporation (国药一致), effective immediately upon submission of his resignation report to the board, while he will continue to hold other positions within the company [1] - For the first half of 2025, the revenue composition of China National Pharmaceutical Group Corporation is as follows: 70.21% from pharmaceutical wholesale, 29.28% from pharmaceutical retail, and 0.51% from other products [1] - As of the time of reporting, the market capitalization of China National Pharmaceutical Group Corporation is 13.8 billion yuan [1]

Market Performance - The three major A-share indices collectively declined in November, with the Shanghai Composite Index falling by 1.67% to close at 3888 points, ending a six-month streak of gains [1] - The Shenzhen Component Index dropped by 2.95% to 12984 points, while the ChiNext Index decreased by 4.23% to 3052 points, marking the second consecutive month of decline for both indices [1] - The North Star 50 Index experienced a significant drop of 12.32% to 1387 points, and the Sci-Tech Innovation 50 Index fell by 6.24% to 1327 points [1] Sector Performance - The top five performing sectors over the past 20 trading days included: - Pharmaceutical Commerce up by 6.65% - Education up by 5.1% - Petroleum Processing and Trade up by 4.83% - Cultural Media up by 4.71% - Apparel and Home Textiles up by 4.5% [1] - Conversely, the bottom five sectors were: - Securities down by 6.16% - Electrical Machinery down by 5.85% - Automation Equipment down by 5.33% - Automotive Parts down by 5.07% - Medical Services down by 4.58% [1] Individual Stock Performance - The top five individual stocks in terms of gains for November were: - Dapeng Industrial up by 553.33% - Danna Biotechnology up by 378.07% - South Network Digital up by 334.45% - Beikong Detection up by 264.63% - Hengkun New Materials up by 228.29% [1] - The bottom five individual stocks in terms of losses were: - Heyuan Biotechnology down by 36.06% - *ST Changyao down by 31.96% - Huide Technology down by 31.47% - Degute down by 29.26% - Bangji Technology down by 26.96% [1]

11月28日，重药控股（000950.SZ）披露下属22家公司合计补缴前期所享受的西部大开发企业所得税优 惠税款及滞纳金总计4430.26万元。 公告显示，重药控股下属子公司重庆医药新特药品有限公司、重庆医药集团医贸药品有限公司、重庆医 药集团药特分有限责任公司、重庆医药集团医疗器械有限公司、重庆医药（集团）股份有限公司、重庆 医药集团陕西有限公司、重庆医药和平医药新产品有限公司、重庆医药集团（宁夏）有限公司、和平泰 康资阳药业有限责任公司、重庆医药上海药品销售有限责任公司、重庆医药集团铭维医疗器械有限公 司、重庆和平吉隆医疗器械有限公司、重庆医药互诚科技有限公司、重庆医药集团绵阳医药有限公司、 重庆医药集团供应链管理有限公司、重庆医药合川医药有限责任公司、重庆医药西南生物新药有限责任 公司、重药控股（宁夏）医药有限公司、重药控股贵州医疗有限公司、重庆医药集团江津医药有限公 司、重药天泽（重庆）医疗器械有限公司、重庆医药天昊医药有限公司，共计22家单位根据各自主管税 务部门的通知，经自查需补缴前期所享受的西部大开发企业所得税优惠税款及滞纳金总计4430.26万 元。上述税款及滞纳金已全部缴纳完毕，主管税务部门 ...

1. Report Industry Investment Rating - There is no information about the report industry investment rating in the provided content. 2. Core Viewpoints of the Report - The inter - bank market liquidity remains loose, with the overnight repurchase rate of deposit - taking institutions staying around 1.32%. The November LPR quotes remain unchanged [4]. - The stock index rose and then fell yesterday, showing an overall volatile performance. It is expected that market differences will be gradually digested during the stock index's volatile adjustment, and the index is expected to rise further with the emergence of new mainlines. The bottom - fishing effect of Central Huijin provides a certain buffer, and the downside risk of the index is generally controllable. The recent market adjustment offers an opportunity to lay out for the further rise of the stock index next year [6]. 3. Summary According to Relevant Catalogs 3.1 Macro - financial Data - **Interest Rates**: DR001 closed at 1.31%, down 0.04bp; DR007 at 1.45%, down 2.79bp; GC001 at 1.38%, down 6.50bp; GC007 at 1.52%, down 1.00bp; SHBOR 3M at 1.58%, up 0.10bp; LPR 5 - year at 3.50%, unchanged; 1 - year treasury bond at 1.35%, down 0.60bp; 5 - year treasury bond at 1.57%, up 0.20bp; 10 - year treasury bond at 1.84%, down 0.10bp; 10 - year US treasury bond at 4.00%, down 1.00bp [3]. - **Central Bank Operations**: The central bank conducted 356.4 billion yuan of 7 - day reverse repurchase operations yesterday at an operating rate of 1.40%. With 300 billion yuan of reverse repurchases maturing on the same day, the net investment for the day was 56.4 billion yuan [3]. 3.2 Stock Index Market - **Closing Prices and Changes**: The CSI 300 closed at 4515, down 0.05%; the SSE 50 at 2972, up 0.02%; the CSI 500 at 6951.3, down 0.2%; the CSI 1000 at 7257.5, up 0.12%. The trading volume of the two stock markets in Shanghai and Shenzhen was 1.7098 trillion yuan, a decrease of 73.6 billion yuan from the previous day. Industry sectors showed mixed performance, with papermaking, batteries, consumer electronics, photovoltaic equipment, and chemical raw materials sectors leading the gains, while cultural media, cement building materials, Internet services, pharmaceutical commerce, and gaming sectors leading the losses [5]. - **Futures Contracts**: IF volume was 100,893, up 3.7%; IF open interest was 264,196, up 1.9%; IH volume was 42,497, up 19.7%; IH open interest was 92,285, up 7.0%; IC volume was 112,976, up 5.6%; IC open interest was 254,570, up 2.2%; IM volume was 183,443, up 3.3%; IM open interest was 364,043, up 0.8% [5]. 3.3 Futures Contract Premium and Discount - **IF**: The premium/discount rates for the current - month, next - month, current - quarter, and next - quarter contracts were 8.38%, 6.21%, 3.95%, and 3.99% respectively [7]. - **IH**: The premium/discount rates for the current - month, next - month, current - quarter, and next - quarter contracts were 5.51%, 3.70%, 1.81%, and 1.63% respectively [7]. - **IC**: The premium/discount rates for the current - month, next - month, current - quarter, and next - quarter contracts were 13.15%, 11.90%, 10.34%, and 11.10% respectively [7]. - **IM**: The premium/discount rates for the current - month, next - month, current - quarter, and next - quarter contracts were 17.93%, 15.48%, 13.47%, and 13.25% respectively [7].

格隆汇11月27日丨重药控股(000950.SZ)公布，公司下属子公司重庆医药新特药品有限公司、重庆医药 集团医贸药品有限公司、重庆医药集团药特分有限责任公司、重庆医药集团医疗器械有限公司、重庆医 药（集团）股份有限公司、重庆医药集团陕西有限公司、重庆医药和平医药新产品有限公司、重庆医药 集团（宁夏）有限公司、和平泰康资阳药业有限责任公司、重庆医药上海药品销售有限责任公司、重庆 医药集团铭维医疗器械有限公司、重庆和平吉隆医疗器械有限公司、重庆医药互诚科技有限公司、重庆 医药集团绵阳医药有限公司、重庆医药集团供应链管理有限公司、重庆医药合川医药有限责任公司、重 庆医药西南生物新药有限责任公司、重药控股（宁夏）医药有限公司、重药控股贵州医疗有限公司、重 庆医药集团江津医药有限公司、重药天泽（重庆）医疗器械有限公司、重庆医药天昊医药有限公司，共 计22家单位根据各自主管税务部门的通知，经自查需补缴前期所享受的西部大开发企业所得税优惠税款 及滞纳金总计4,430.26万元。截至本公告披露日，上述税款及滞纳金已全部缴纳完毕，主管税务部门未 对该事项予以处罚。 ...

重药控股公告称，下属22家子公司根据主管税务部门通知，自查后需补缴前期西部大开发企业所得税优 惠税款及滞纳金4430.26万元，截至公告披露日已全部缴清，且未受处罚。该事项不属于前期会计差 错，不追溯调整前期财务数据，补缴款项将计入2025年当期损益，对2025年净利润的具体影响以审计后 财报为准，不影响公司正常经营。 ...

Group 1 - Several companies, including Shuyupingmin, Huaren Health, and Kaikai Industry, experienced a decline of over 6% [1] - Other companies such as Yaoyigou, Renmintongtai, Yingtigroup, Diyi Medical, and Yifeng Pharmacy also followed the downward trend [1]

Group 1 - A-shares experienced a net outflow of 18.622 billion yuan in main funds on November 27, with five industries seeing net inflows, including light industry manufacturing, real estate, and food and beverage [1][2] - The top three industries with net inflows were light industry manufacturing (4.71 billion yuan), real estate (1.82 billion yuan), and food and beverage (1.44 billion yuan) [1] - The computer and media industries had the highest net outflows, each exceeding 3.5 billion yuan, while telecommunications, biomedicine, and machinery equipment also saw significant outflows [1] Group 2 - ZTE Corporation led with a net inflow of 915 million yuan, attributed to the successful mass production of a high-performance chip developed by its subsidiary [2][3] - Annie Co., Ltd. followed with a net inflow of 398 million yuan, with a notable increase in trading volume and net purchases from specific brokerage firms [2][3] - A total of 50 stocks saw net inflows exceeding 100 million yuan, with 14 stocks exceeding 200 million yuan [1][3] Group 3 - The top stocks with net inflows included ZTE Corporation (915 million yuan), Annie Co., Ltd. (398 million yuan), and Shannon Chip (384 million yuan) [3] - Conversely, the stocks with the highest net outflows included Zhongji Xuchuang (1.479 billion yuan), Huhua Electric (954 million yuan), and Ningde Times (806 million yuan) [4][7] - The tail-end trading saw significant net inflows in the pharmaceutical sector, particularly for stocks like Te Yi Pharmaceutical and Han De Information, both exceeding 100 million yuan [5][6]

Core Viewpoint - The increase in accounts receivable for China National Pharmaceutical Group Corporation (国药股份) is attributed to multiple factors, including business expansion, sales growth, and management strategies aimed at optimizing accounts receivable structure [1] Group 1: Factors Contributing to Accounts Receivable Increase - The company's business scale expansion and sales revenue growth have led to a corresponding increase in total accounts receivable [1] - The company is managing a dynamic balance between collection cycles and factoring discount costs, which has resulted in a reduction of the factoring scale for accounts receivable financing [1] - The collection cycles are also related to the periodic payment behaviors of clients, with some clients typically concentrating their payments at year-end [1] Group 2: Management Strategies - The company is committed to optimizing accounts receivable management through enhanced customer credit assessments and improved collection processes [1] - Measures are in place to ensure timely recovery of accounts receivable [1]